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 Large spectrum of severity 
& symptoms 
Mucopolysaccharidoses (MPS)





Molecular study of Portuguese patients
16 unrelated Portuguese patients; 
15 different mutations;
MPS II
11 Portuguese patients; 
5 novel mutations. 











































MPS IIIA and IIIB
Molecular study of Portuguese patients
3 patients; 


















Molecular study of Portuguese patients
Molecular study of Tunisian patients
Next-generation-sequencing (NGS) as an approach for the diagnosis of LSDs
Our current NGS-based workflow gene panel seems to be a valid tool for 
the genetic analysis of the classical LSDs associated genes. 





 Available for 4 MPSs




– Ineffective for the CNS manifestations
• ‘Broader’ approaches
i.e. 1 therapy 1 disease
(or even more!)
• ‘Personalized’ approaches
i.e. 1 therapy for each mutation/
type of mutation




able to cross the BBB

























“With research, possibilities are limitless”…
• ‘Personalized’ approaches
Final goal: 





promote their transport into the lysosome
“With research, possibilities are limitless”…
• ‘Personalized’ approaches
Final goal: 







“With research, possibilities are limitless”…
• ‘Personalized’ approaches
Final goal: 
correction/amellioration of 1 mutation in particular
type of mutations
How?
 Correction of splicing mutations


“With research, possibilities are limitless”…
Our work at INSA…
• ‘Broader’ approaches
– gSRT for MPS
• ‘Personalized’ approaches




‘Easy’ to test at a cellular level – 1st stage
• ‘Broader’ approach
• Targets: genes from the GAGs biosynthetic pathway
gSRT for MucoPoliSacharidoses
• ‘Broader’ approach






• The MPS III example






• The MPS III example
gSRT for MucoPoliSacharidoses
gSRT for MucoPolySaccharidosis type III
siRNA
MPS III fibroblasts 
Promising results!
Reasons to keep studying...
• ‘Personalized’ approach
Splicing Therapies for LSD
 The MPS example
 MPS III C  
 Splicing mutations frequent (~20%)






good motifs to attempt splicing correction as 
a therapeutic approach!
Matos et al. Orphanet Journal of Rare Diseases, 2014
c.234+1G>A
Splicing Therapies for LSD
 The MPS example
 MPS III C  
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MPS IIIC fibroblasts 
4  ≠ oligos
comp. 
1-4
Splicing Therapies for LSD
 The MPS example
 MPS III C  
Matos et al. Orphanet Journal of Rare Diseases, 2014
Molecule 
(U1 snRNAs)
MPS IIIC fibroblasts 
Splicing Therapies for LSD
Promising results!
Reasons to keep studying...
• in vivo studies
A look forward…
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• in vivo studies
A look forward…
• Design a proper siRNA delivery strategy 
for therapeutic purposes
A look forward…
 Coupling of specific ligands
to siRNA-carring liposomes
o Transferrin (Tf)
o Rabies virus peptide
derivative (RGV-2r)
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MPS cell lines were provided by 
“The Cell Line and DNA Biobank
from Patients Affected by 
Genetic Diseases”’
Obrigada!
